Galenica Reports Steady 2022 Growth and Confirms 2023 Earnings Outlook
• Galenica reported increased full-year sales across all segments, leading to a confirmed 2023 earnings outlook • Full-year sales rose 4.4% to 3.75 billion Swiss francs, attributed to positive pharmaceutical market development • Sales grew slower at 3.3% in H2 2023 vs 5.5% in H1 due to seasonal flu and coronavirus in H2 2022 • Outlook for 2023 maintained - expected EBIT of 200.8 million francs, roughly same as 2022 • 2023 dividend guidance at least at same level as 2022; full results on March 12